Salts and solid state forms of plinabulin

Abstract

The present disclosure relates to Plinabulin solid state forms, Plinabulin salts including hydrochloride and solid state forms thereof, processes for preparation thereof and pharmaceutical compositions thereof.

1 . A crystalline form of Plinabulin designated as Form T, characterized by:
 a. an X-ray powder diffraction pattern having peaks at 8.2, 9.5, 16.4, 21.5 and 24.7 degrees 2-theta±0.2 degrees 2-theta, and also having one, two, three, four or five additional peaks selected from 12.1, 14.0, 15.0, 18.4 and 22.5 degrees two theta±0.2 degrees two theta; or   b. an XRPD pattern as depicted in  FIG. 16 .   
     
     
         2 . The crystalline Form T of Plinabulin according to  claim 1 , characterized by an XRPD pattern having peaks at 8.2, 9.5, 16.4, 21.5 and 24.7 degrees 2-theta±0.2 degrees 2-theta, and also having one, two, three, four or five additional peaks selected from 12.1, 14.0, 15.0, 18.4 and 22.5 degrees two theta±0.2 degrees two theta. 
     
     
         3 . A crystalline form of Plinabulin designated as Form T, characterized by an X-ray powder diffraction pattern having peaks at 8.2, 9.5, 12.1, 14.0, 15.0, 16.4, 18.4, 21.5, 22.5 and 24.7 degrees 2-theta±0.2 degrees 2-theta. 
     
     
         4 . The crystalline Form T according to  claim 1 , which is monohydrate. 
     
     
         5 . A pharmaceutical composition comprising the crystalline Form T according to  claim 1 . 
     
     
         6 . A pharmaceutical formulation comprising the crystalline Form T according to  claim 1 , and at least one pharmaceutically acceptable excipient. 
     
     
         7 . A process for preparing a pharmaceutical formulation, comprising combining the crystalline Form T according to  claim 1  with at least one pharmaceutically acceptable excipient. 
     
     
         8 . The crystalline Form T according to  claim 1 , for use as a medicament. 
     
     
         9 . The crystalline Form T, according to  claim 1 , for use in the treatment of cancer. 
     
     
         10 . The crystalline Form T, according to  claim 1 , for the manufacture of medicament for treating cancer.